Sarepta Shares Soar 37% Following Expanded Approval for Elevidys
By Josh Beckerman
Shares of Sarepta Therapeutics rose 37% to $169.15 in after-hours trading on Thursday after the Food and Drug Administration approved an expanded indication for its Duchenne muscular dystrophy treatment Elevidys.
The drug was approved for ambulatory and non-ambulatory people, ages 4 and above, with a confirmed mutation in the DMD gene. This includes traditional approval for ambulatory patients and accelerated approval for non-ambulatory patients, the company said.
Under the accelerated-approval program, the FDA clears the use of drugs faster than it normally would and asks companies to conduct follow-up studies.
In December 2019, Sarepta announced a licensing agreement that provided Roche Holding exclusive rights to the drug outside the U.S.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
June 20, 2024 19:05 ET (23:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now